Please login to the form below

Not currently logged in

Moderna to launch Innovation and Technology Center in the UK

With support from the UK government, the manufacturing facility is expected to produce up to 250 million doses annually


Moderna, a biotech company specialising in messenger RNA (mRNA) therapeutics and vaccines, and the UK government have reached an agreement in principle for an mRNA Innovation and Technology Center in the UK.

Throughout the COVID-19 pandemic, Moderna worked with governments, healthcare professionals and other key stakeholders to help combat the virus and future pathogens.

The company, with the support of the UK government, plans to use the site to produce mRNA vaccines, including vaccines for COVID-19, seasonal influenza, respiratory syncytial virus (RSV) and other potential vaccine candidates.

Stéphane Bancel, chief executive officer of Moderna, said: "We are excited to be able to continue our collaboration with the UK government and Vaccine Taskforce with this new mRNA Innovation and Technology Center in the UK. The UK has established a world-class life sciences and research community.

"We are committed to global public health, and as we continue to expand internationally, we are pleased to bring local mRNA manufacturing to the UK. We look forward to establishing our R&D activities and capabilities in the country."

It is hoped that the site will bolster the UK’s international effort to reduce the impact of future pandemics as part of its ‘100 days mission’ plan.

The company also intends to further expand its UK presence through R&D funding.

Although Moderna has not yet disclosed the cost of the facility, according to the Financial Times, the site is expected to be worth up to £1bn ($1.2bn) and will manufacture up to 250 million doses each year. The agreement covers a ten-year time frame and will be finalised this summer.

Moderna is collaborating with the National Institute for Health Research (NIHR) on a phase 3 study in the UK, investigating Moderna's bivalent Omicron-containing booster candidate (mRNA-1273.214).

Article by
Fleur Jeffries

23rd June 2022

From: Research, Healthcare



Subscribe to our email news alerts

Featured jobs


Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

Report: Omnichannel advice for the life science industry
In the latest issue of Delta magazine, Fishawack Health's Medical, Marketing, and Consulting experts share their practical advice for creating meaningful omnichannel stakeholder experiences and reveal our proprietary tool for...
Virtual MSL/Sales training programs and events
Top 10 ways to leverage the Impetus InSite Platform® for internal MSL/Sales training programs and events...
6 trends shaping the future of personalized medicine
Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....